Fund will consist of 30-50 holdings
CEO Fink pledges more action on diversity
Overall shareholder base voted to maintain £201m trust
Main focus on pharma and biotech
Manager of £1.2bn fund leaving in Q2
Seven-year stint comes to an end
Announced intention to list earlier in April
To work within DFM team
Director of business development